bladder%20cancer
BLADDER CANCER

Bladder cancer is a heterogenous neoplasm that ranges from non-life-threatening, low-grade, superficial papillary lesions to high-grade invasive tumors that often metastasizes at the presentation.

It is the most common cancer involving the urinary system and it is the 11th most commonly diagnosed in the world.

Microscopic or gross painless hematuria is the most common presenting complaint.

Radiotherapy

Radical Radiotherapy

  • For muscle-invasive bladder cancer, radical radiotherapy is given using a radiosensitiser (eg Mitomycin in combination w/ Fluorouracil or carbogen in combination w/ Nicotinamide)
  • Alternative treatment in patients unfit for radical surgery
  • Preoperative radiotherapy is not recommended to improve survival
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
01 Nov 2017
High-grade serous carcinomas (HGSCs) of the pelvis, whether associated with serous tubal intra-epithelial carcinoma lesions or not, appear to have shared biologic origin in the distal fallopian tube, according to a recent study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.